Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Follicular Lymphoma Treatment Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Follicular Lymphoma Treatment Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Follicular Lymphoma Treatment Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Chemotherapy
    • 1.4.3 Radiotherapy
    • 1.4.4 Monoclonal Antibodies
    • 1.4.5 Stem Cell Transplantation
  • 1.5 Market by Application
    • 1.5.1 Global Follicular Lymphoma Treatment Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospital
    • 1.5.3 Clinic
    • 1.5.4 Others
  • 1.6 Coronavirus Disease 2019 (Covid-19): Follicular Lymphoma Treatment Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Follicular Lymphoma Treatment Industry
      • 1.6.1.1 Follicular Lymphoma Treatment Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Follicular Lymphoma Treatment Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Follicular Lymphoma Treatment Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Follicular Lymphoma Treatment Market Perspective (2015-2026)
  • 2.2 Follicular Lymphoma Treatment Growth Trends by Regions
    • 2.2.1 Follicular Lymphoma Treatment Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Follicular Lymphoma Treatment Historic Market Share by Regions (2015-2020)
    • 2.2.3 Follicular Lymphoma Treatment Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Follicular Lymphoma Treatment Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Follicular Lymphoma Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Follicular Lymphoma Treatment Players by Market Size
    • 3.1.1 Global Top Follicular Lymphoma Treatment Players by Revenue (2015-2020)
    • 3.1.2 Global Follicular Lymphoma Treatment Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Follicular Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Follicular Lymphoma Treatment Market Concentration Ratio
    • 3.2.1 Global Follicular Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Follicular Lymphoma Treatment Revenue in 2019
  • 3.3 Follicular Lymphoma Treatment Key Players Head office and Area Served
  • 3.4 Key Players Follicular Lymphoma Treatment Product Solution and Service
  • 3.5 Date of Enter into Follicular Lymphoma Treatment Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Follicular Lymphoma Treatment Historic Market Size by Type (2015-2020)
  • 4.2 Global Follicular Lymphoma Treatment Forecasted Market Size by Type (2021-2026)

5 Follicular Lymphoma Treatment Breakdown Data by Application (2015-2026)

  • 5.1 Global Follicular Lymphoma Treatment Market Size by Application (2015-2020)
  • 5.2 Global Follicular Lymphoma Treatment Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Follicular Lymphoma Treatment Market Size (2015-2020)
  • 6.2 Follicular Lymphoma Treatment Key Players in North America (2019-2020)
  • 6.3 North America Follicular Lymphoma Treatment Market Size by Type (2015-2020)
  • 6.4 North America Follicular Lymphoma Treatment Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Follicular Lymphoma Treatment Market Size (2015-2020)
  • 7.2 Follicular Lymphoma Treatment Key Players in Europe (2019-2020)
  • 7.3 Europe Follicular Lymphoma Treatment Market Size by Type (2015-2020)
  • 7.4 Europe Follicular Lymphoma Treatment Market Size by Application (2015-2020)

8 China

  • 8.1 China Follicular Lymphoma Treatment Market Size (2015-2020)
  • 8.2 Follicular Lymphoma Treatment Key Players in China (2019-2020)
  • 8.3 China Follicular Lymphoma Treatment Market Size by Type (2015-2020)
  • 8.4 China Follicular Lymphoma Treatment Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Follicular Lymphoma Treatment Market Size (2015-2020)
  • 9.2 Follicular Lymphoma Treatment Key Players in Japan (2019-2020)
  • 9.3 Japan Follicular Lymphoma Treatment Market Size by Type (2015-2020)
  • 9.4 Japan Follicular Lymphoma Treatment Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Follicular Lymphoma Treatment Market Size (2015-2020)
  • 10.2 Follicular Lymphoma Treatment Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Follicular Lymphoma Treatment Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Follicular Lymphoma Treatment Market Size by Application (2015-2020)

11 India

  • 11.1 India Follicular Lymphoma Treatment Market Size (2015-2020)
  • 11.2 Follicular Lymphoma Treatment Key Players in India (2019-2020)
  • 11.3 India Follicular Lymphoma Treatment Market Size by Type (2015-2020)
  • 11.4 India Follicular Lymphoma Treatment Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Follicular Lymphoma Treatment Market Size (2015-2020)
  • 12.2 Follicular Lymphoma Treatment Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Follicular Lymphoma Treatment Market Size by Type (2015-2020)
  • 12.4 Central & South America Follicular Lymphoma Treatment Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Boehringer Ingelheim GmbH
    • 13.1.1 Boehringer Ingelheim GmbH Company Details
    • 13.1.2 Boehringer Ingelheim GmbH Business Overview and Its Total Revenue
    • 13.1.3 Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Introduction
    • 13.1.4 Boehringer Ingelheim GmbH Revenue in Follicular Lymphoma Treatment Business (2015-2020))
    • 13.1.5 Boehringer Ingelheim GmbH Recent Development
  • 13.2 Bristol-Myers Squibb Company
    • 13.2.1 Bristol-Myers Squibb Company Company Details
    • 13.2.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
    • 13.2.3 Bristol-Myers Squibb Company Follicular Lymphoma Treatment Introduction
    • 13.2.4 Bristol-Myers Squibb Company Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 13.2.5 Bristol-Myers Squibb Company Recent Development
  • 13.3 Celgene Corporation
    • 13.3.1 Celgene Corporation Company Details
    • 13.3.2 Celgene Corporation Business Overview and Its Total Revenue
    • 13.3.3 Celgene Corporation Follicular Lymphoma Treatment Introduction
    • 13.3.4 Celgene Corporation Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 13.3.5 Celgene Corporation Recent Development
  • 13.4 Celldex Therapeutics, Inc.
    • 13.4.1 Celldex Therapeutics, Inc. Company Details
    • 13.4.2 Celldex Therapeutics, Inc. Business Overview and Its Total Revenue
    • 13.4.3 Celldex Therapeutics, Inc. Follicular Lymphoma Treatment Introduction
    • 13.4.4 Celldex Therapeutics, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 13.4.5 Celldex Therapeutics, Inc. Recent Development
  • 13.5 Celltrion, Inc.
    • 13.5.1 Celltrion, Inc. Company Details
    • 13.5.2 Celltrion, Inc. Business Overview and Its Total Revenue
    • 13.5.3 Celltrion, Inc. Follicular Lymphoma Treatment Introduction
    • 13.5.4 Celltrion, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 13.5.5 Celltrion, Inc. Recent Development
  • 13.6 Cellular Biomedicine Group, Inc.
    • 13.6.1 Cellular Biomedicine Group, Inc. Company Details
    • 13.6.2 Cellular Biomedicine Group, Inc. Business Overview and Its Total Revenue
    • 13.6.3 Cellular Biomedicine Group, Inc. Follicular Lymphoma Treatment Introduction
    • 13.6.4 Cellular Biomedicine Group, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 13.6.5 Cellular Biomedicine Group, Inc. Recent Development
  • 13.7 Coherus BioSciences, Inc.
    • 13.7.1 Coherus BioSciences, Inc. Company Details
    • 13.7.2 Coherus BioSciences, Inc. Business Overview and Its Total Revenue
    • 13.7.3 Coherus BioSciences, Inc. Follicular Lymphoma Treatment Introduction
    • 13.7.4 Coherus BioSciences, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 13.7.5 Coherus BioSciences, Inc. Recent Development
  • 13.8 CTI BioPharma Corp.
    • 13.8.1 CTI BioPharma Corp. Company Details
    • 13.8.2 CTI BioPharma Corp. Business Overview and Its Total Revenue
    • 13.8.3 CTI BioPharma Corp. Follicular Lymphoma Treatment Introduction
    • 13.8.4 CTI BioPharma Corp. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 13.8.5 CTI BioPharma Corp. Recent Development
  • 13.9 Curis, Inc.
    • 13.9.1 Curis, Inc. Company Details
    • 13.9.2 Curis, Inc. Business Overview and Its Total Revenue
    • 13.9.3 Curis, Inc. Follicular Lymphoma Treatment Introduction
    • 13.9.4 Curis, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 13.9.5 Curis, Inc. Recent Development
  • 13.10 Dynavax Technologies Corporation
    • 13.10.1 Dynavax Technologies Corporation Company Details
    • 13.10.2 Dynavax Technologies Corporation Business Overview and Its Total Revenue
    • 13.10.3 Dynavax Technologies Corporation Follicular Lymphoma Treatment Introduction
    • 13.10.4 Dynavax Technologies Corporation Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 13.10.5 Dynavax Technologies Corporation Recent Development
  • 13.11 Eisai
    • 10.11.1 Eisai Company Details
    • 10.11.2 Eisai Business Overview and Its Total Revenue
    • 10.11.3 Eisai Follicular Lymphoma Treatment Introduction
    • 10.11.4 Eisai Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 10.11.5 Eisai Recent Development
  • 13.12 EpiZyme, Inc.
    • 10.12.1 EpiZyme, Inc. Company Details
    • 10.12.2 EpiZyme, Inc. Business Overview and Its Total Revenue
    • 10.12.3 EpiZyme, Inc. Follicular Lymphoma Treatment Introduction
    • 10.12.4 EpiZyme, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 10.12.5 EpiZyme, Inc. Recent Development
  • 13.13 F. Hoffmann-La Roche Ltd.
    • 10.13.1 F. Hoffmann-La Roche Ltd. Company Details
    • 10.13.2 F. Hoffmann-La Roche Ltd. Business Overview and Its Total Revenue
    • 10.13.3 F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Introduction
    • 10.13.4 F. Hoffmann-La Roche Ltd. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 10.13.5 F. Hoffmann-La Roche Ltd. Recent Development
  • 13.14 Genentech, Inc.
    • 10.14.1 Genentech, Inc. Company Details
    • 10.14.2 Genentech, Inc. Business Overview and Its Total Revenue
    • 10.14.3 Genentech, Inc. Follicular Lymphoma Treatment Introduction
    • 10.14.4 Genentech, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 10.14.5 Genentech, Inc. Recent Development
  • 13.15 Gilead Sciences, Inc.
    • 10.15.1 Gilead Sciences, Inc. Company Details
    • 10.15.2 Gilead Sciences, Inc. Business Overview and Its Total Revenue
    • 10.15.3 Gilead Sciences, Inc. Follicular Lymphoma Treatment Introduction
    • 10.15.4 Gilead Sciences, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 10.15.5 Gilead Sciences, Inc. Recent Development
  • 13.16 GlaxoSmithKline Plc
    • 10.16.1 GlaxoSmithKline Plc Company Details
    • 10.16.2 GlaxoSmithKline Plc Business Overview and Its Total Revenue
    • 10.16.3 GlaxoSmithKline Plc Follicular Lymphoma Treatment Introduction
    • 10.16.4 GlaxoSmithKline Plc Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 10.16.5 GlaxoSmithKline Plc Recent Development
  • 13.17 Hutchison MediPharma Limited
    • 10.17.1 Hutchison MediPharma Limited Company Details
    • 10.17.2 Hutchison MediPharma Limited Business Overview and Its Total Revenue
    • 10.17.3 Hutchison MediPharma Limited Follicular Lymphoma Treatment Introduction
    • 10.17.4 Hutchison MediPharma Limited Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 10.17.5 Hutchison MediPharma Limited Recent Development
  • 13.18 Immune Design Corp.
    • 10.18.1 Immune Design Corp. Company Details
    • 10.18.2 Immune Design Corp. Business Overview and Its Total Revenue
    • 10.18.3 Immune Design Corp. Follicular Lymphoma Treatment Introduction
    • 10.18.4 Immune Design Corp. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 10.18.5 Immune Design Corp. Recent Development
  • 13.19 ImmunoGen, Inc.
    • 10.19.1 ImmunoGen, Inc. Company Details
    • 10.19.2 ImmunoGen, Inc. Business Overview and Its Total Revenue
    • 10.19.3 ImmunoGen, Inc. Follicular Lymphoma Treatment Introduction
    • 10.19.4 ImmunoGen, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
    • 10.19.5 ImmunoGen, Inc. Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Follicular Lymphoma Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Follicular Lymphoma Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Celgene Corporation
    Celldex Therapeutics, Inc.
    Celltrion, Inc.
    Cellular Biomedicine Group, Inc.
    Coherus BioSciences, Inc.
    CTI BioPharma Corp.
    Curis, Inc.
    Dynavax Technologies Corporation
    Eisai
    EpiZyme, Inc.
    F. Hoffmann-La Roche Ltd.
    Genentech, Inc.
    Gilead Sciences, Inc.
    GlaxoSmithKline Plc
    Hutchison MediPharma Limited
    Immune Design Corp.
    ImmunoGen, Inc.

    Market segment by Type, the product can be split into
    Chemotherapy
    Radiotherapy
    Monoclonal Antibodies
    Stem Cell Transplantation
    Market segment by Application, split into
    Hospital
    Clinic
    Others

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Follicular Lymphoma Treatment status, future forecast, growth opportunity, key market and key players.
    To present the Follicular Lymphoma Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Follicular Lymphoma Treatment are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now